Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors

First global approval of a once-daily, orally administered, Complement Factor B inhibitorApproval based on robust efficacy and safety data from ...
Le Lézard

Precision Diabetes and Nagase Diagnostics Announce Exclusive U.S. Commercialization Partnership for Lucica® Glycated Albumin-L, the Only FDA-Cleared Assay Specifically ...

Precision Diabetes, Inc. and Nagase Diagnostics Co., Ltd. today announced an exclusive U.S. commercialization partnership for the Lucica®GlycatedAlbumin(GA)-Lassay (510(k) No. K170147), the only assay ...